 BOSTON, Aug. 24, 2021 PRNewswire -- Stealth BioTherapeutics Corp Nasdaq: MITO, a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced the submission of a New Drug Application NDA to the U.S. Food and Drug Adminstration FDA for elamipretide, the companys lead product candidate, for the treatment of Barth syndrome, an ultra-rare genetic condition with no FDA- or EMA-approved therapies. Children and young adults affected by Barth syndrome are suffering from life limiting, progressive cardiomyopathy, exercise intolerance, and debilitating fatigue for which there are no approved treatment options, said Chief Executive Officer Reenie McCarthy. 